147 related articles for article (PubMed ID: 20215641)
1. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia.
van der Linden MH; Seslija L; Schneider P; Driessen EM; Castro PG; Stumpel DJ; van Roon E; de Boer J; Williams O; Pieters R; Stam RW
PLoS One; 2015; 10(3):e0120326. PubMed ID: 25793396
[TBL] [Abstract][Full Text] [Related]
3. Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
Fechina L; Popov A; Tsaur G; Henze G; Shorikov E; Makarova O; Khlebnikova O; Zhukova Y; Arakaev O; Streneva O; Verzhbitskaya T; Riger T; Solodovnikov A; Lapotentova E; Aleinikova O; Myakova N; Boichenko E; Kondratchik K; Nikonova O; Shapochnik A; Goroshkova M; Ponomareva N; Novichkova G; Karachunskiy A; Roumiantsev A
Leukemia; 2023 Nov; 37(11):2276-2281. PubMed ID: 37741948
[No Abstract] [Full Text] [Related]
4. [Effects of DNA methylation on ABO gene expression in leukemia].
Shao M; Lyu XP; Yang QK; Zhu WT; Song J; Kong YK; Wang J; Sun L; Wang F
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):795-799. PubMed ID: 27719724
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Wei H; Xiang L; Wayne AS; Chertov O; FitzGerald DJ; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2012 May; 109(18):6898-903. PubMed ID: 22509046
[TBL] [Abstract][Full Text] [Related]
6. Trans-regulated silencing and reactivation of TP53 tumor suppressor gene in malignant transformation and its reversion.
Yang L; Sasaki MS
Jpn J Cancer Res; 2000 Nov; 91(11):1111-8. PubMed ID: 11092975
[TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Kagan AB; Garrison DA; Anders NM; Webster JA; Baker SD; Yegnasubramanian S; Rudek MA
Clin Transl Sci; 2023 Aug; 16(8):1309-1322. PubMed ID: 37345219
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation as a potential mediator of environmental risks in the development of childhood acute lymphoblastic leukemia.
Timms JA; Relton CL; Rankin J; Strathdee G; McKay JA
Epigenomics; 2016 Apr; 8(4):519-36. PubMed ID: 27035209
[TBL] [Abstract][Full Text] [Related]
9. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics of acute lymphocytic leukemia.
Garcia-Manero G; Yang H; Kuang SQ; O'Brien S; Thomas D; Kantarjian H
Semin Hematol; 2009 Jan; 46(1):24-32. PubMed ID: 19100365
[TBL] [Abstract][Full Text] [Related]
11. Improving cancer immunotherapy with DNA methyltransferase inhibitors.
Saleh MH; Wang L; Goldberg MS
Cancer Immunol Immunother; 2016 Jul; 65(7):787-96. PubMed ID: 26646852
[TBL] [Abstract][Full Text] [Related]
12. Increased MYB alternative promoter usage is associated with relapse in acute lymphoblastic leukemia.
Fehr A; Arvidsson G; Nordlund J; Lönnerholm G; Stenman G; Andersson MK
Genes Chromosomes Cancer; 2023 Oct; 62(10):597-606. PubMed ID: 37218648
[TBL] [Abstract][Full Text] [Related]
13. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Kremens B; Lehrnbecher T; von Neuhoff C; Sander A; von Stackelberg A; Schmid I; Starý J; Steinbach D; Vormoor J; Reinhardt D
Leukemia; 2012 Apr; 26(4):654-61. PubMed ID: 21968880
[TBL] [Abstract][Full Text] [Related]
14. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.
Munir F; He J; Connors J; Garcia M; Gibson A; McCall D; Nunez C; Dinh CN; Robusto L; Roth M; Khazal S; Tewari P; Cuglievan B
Transl Pediatr; 2023 Mar; 12(3):487-502. PubMed ID: 37035397
[TBL] [Abstract][Full Text] [Related]
15. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy.
Kotecha RS
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):611-617. PubMed ID: 36485124
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
17. Decitabine mildly attenuates
Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
[No Abstract] [Full Text] [Related]
18. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.
Meyer LK; Hermiston ML
Cancer Drug Resist; 2019; 2(2):313-325. PubMed ID: 35582725
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Drug Library Screening in Primary
Wander P; Arentsen-Peters STCJM; Vrenken KS; Pinhanҫos SM; Koopmans B; Dolman MEM; Jones L; Garrido Castro P; Schneider P; Kerstjens M; Molenaar JJ; Pieters R; Zwaan CM; Stam RW
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327440
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
